JP7009463B2 - 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法 - Google Patents

細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法 Download PDF

Info

Publication number
JP7009463B2
JP7009463B2 JP2019518343A JP2019518343A JP7009463B2 JP 7009463 B2 JP7009463 B2 JP 7009463B2 JP 2019518343 A JP2019518343 A JP 2019518343A JP 2019518343 A JP2019518343 A JP 2019518343A JP 7009463 B2 JP7009463 B2 JP 7009463B2
Authority
JP
Japan
Prior art keywords
cells
cell
analog
celastrol
tissues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019518343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523784A5 (https=
JP2019523784A (ja
Inventor
シャント・デル・サルキシアン
ニコラ・ノワジュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019523784A publication Critical patent/JP2019523784A/ja
Publication of JP2019523784A5 publication Critical patent/JP2019523784A5/ja
Priority to JP2022003014A priority Critical patent/JP2022062037A/ja
Application granted granted Critical
Publication of JP7009463B2 publication Critical patent/JP7009463B2/ja
Priority to JP2023208559A priority patent/JP2024019483A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/128—Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019518343A 2016-06-15 2017-06-15 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法 Active JP7009463B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022003014A JP2022062037A (ja) 2016-06-15 2022-01-12 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法
JP2023208559A JP2024019483A (ja) 2016-06-15 2023-12-11 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350258P 2016-06-15 2016-06-15
US62/350,258 2016-06-15
PCT/CA2017/000151 WO2017214709A1 (en) 2016-06-15 2017-06-15 Reagents, compositions and methods for improving viability and function of cells, tissues and organs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022003014A Division JP2022062037A (ja) 2016-06-15 2022-01-12 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法

Publications (3)

Publication Number Publication Date
JP2019523784A JP2019523784A (ja) 2019-08-29
JP2019523784A5 JP2019523784A5 (https=) 2020-07-30
JP7009463B2 true JP7009463B2 (ja) 2022-01-25

Family

ID=60663810

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019518343A Active JP7009463B2 (ja) 2016-06-15 2017-06-15 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法
JP2022003014A Pending JP2022062037A (ja) 2016-06-15 2022-01-12 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法
JP2023208559A Pending JP2024019483A (ja) 2016-06-15 2023-12-11 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022003014A Pending JP2022062037A (ja) 2016-06-15 2022-01-12 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法
JP2023208559A Pending JP2024019483A (ja) 2016-06-15 2023-12-11 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法

Country Status (9)

Country Link
US (2) US11446265B2 (https=)
EP (1) EP3471733B1 (https=)
JP (3) JP7009463B2 (https=)
CN (2) CN109803664A (https=)
AU (1) AU2017285486B2 (https=)
CA (1) CA3027682A1 (https=)
DK (1) DK3471733T3 (https=)
ES (1) ES2992544T3 (https=)
WO (1) WO2017214709A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055817A1 (en) * 2017-09-14 2019-03-21 The Regents Of The University Of California EX VIVO CONSERVATION AND EXPANSION OF STEM CELLS
JP7404246B2 (ja) * 2018-02-14 2023-12-25 ソシエテ・デ・プロデュイ・ネスレ・エス・アー フォン・ヴィレブランド因子のレベルを調節する化合物、及び血液疾患の治療におけるそれらの使用
EP3833662B1 (en) 2018-08-20 2024-01-17 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
WO2021055985A1 (en) * 2019-09-22 2021-03-25 Cellerant Therapeutics, Inc. Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
US20220023345A1 (en) * 2020-07-22 2022-01-27 Caladrius Biosciences, Inc. Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection
CN112375802A (zh) * 2020-11-06 2021-02-19 中国科学院城市环境研究所 评价白藜芦醇干预肺上皮细胞多环芳烃毒性效应的试剂或试剂盒及其应用和检测
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
WO2022212878A1 (en) * 2021-04-01 2022-10-06 The Regents Of The University Of California Human pluripotent stem cell-derived secretome as a biologic for prevention and treatment of neurodegenerative and apoptotic diseases
CN118634317B (zh) * 2024-08-16 2024-10-22 四川大学 乳铁蛋白联合麦角硫因在制备预防和/或治疗阿尔茨海默症的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110218143A1 (en) 2007-11-20 2011-09-08 University Of Florida Research Foundation Compositions and methods for tissue repair
US20110311508A1 (en) 2008-12-08 2011-12-22 Northwestern University Method of modulating hsf-1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1112181C (zh) 2000-05-26 2003-06-25 北京大学 雷公藤属植物提取物在制备预防和治疗神经系统疾病药上的应用
KR20080031474A (ko) 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
AU2006272497B2 (en) 2005-07-27 2012-07-19 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US20100204093A1 (en) 2006-07-27 2010-08-12 University Of Florida Research Foundation, Inc Use of heat shock activators for tissue regeneration
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2008063513A2 (en) 2006-11-13 2008-05-29 Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
CN101288671B (zh) 2008-04-17 2010-12-01 首都医科大学 雷公藤单体化合物在提高腺相关病毒载体介导的基因表达效率及其对神经退行性疾病的辅助治疗中的用途
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
CN101756956A (zh) 2009-03-25 2010-06-30 赵亚力 儿茶素在制备逆转录病毒整合酶抑制剂中的应用
CN103524592B (zh) * 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
CA3044998A1 (en) 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110218143A1 (en) 2007-11-20 2011-09-08 University Of Florida Research Foundation Compositions and methods for tissue repair
US20110311508A1 (en) 2008-12-08 2011-12-22 Northwestern University Method of modulating hsf-1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ACS Chemical Biology，2012年，7，928-937
British Journal of Pharmacology，2014年，171，5265-5279
Canadian Journal of Cardiology，2012年，28(5):Suppl，S297，doi:10.1016/j.cjca.2012.07.485
Journal of the American Chemical Society，2011年，133，19634-19637
The Journal of Biological Chemistry，2004年，279(53)，56053-56060
Trends in Pharmacological Sciences，2015年，36(1)，6-14

Also Published As

Publication number Publication date
US20230024103A1 (en) 2023-01-26
US20210169830A1 (en) 2021-06-10
US11446265B2 (en) 2022-09-20
JP2022062037A (ja) 2022-04-19
CN121313845A (zh) 2026-01-13
EP3471733A4 (en) 2020-02-05
WO2017214709A8 (en) 2018-12-13
AU2017285486A1 (en) 2019-02-07
EP3471733B1 (en) 2024-08-07
CN109803664A (zh) 2019-05-24
DK3471733T3 (da) 2024-10-14
ES2992544T3 (es) 2024-12-13
EP3471733A1 (en) 2019-04-24
JP2019523784A (ja) 2019-08-29
CA3027682A1 (en) 2017-12-21
AU2017285486B2 (en) 2023-04-27
US12419849B2 (en) 2025-09-23
JP2024019483A (ja) 2024-02-09
WO2017214709A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
JP7009463B2 (ja) 細胞、組織、および器官の生存能および機能を向上させるための試薬、組成物、および方法
Gaebel et al. Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration
Saito et al. Xenotransplant cardiac chimera: immune tolerance of adult stem cells
Lee et al. Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes
Tian et al. Mesenchymal stem cells improve mouse non-heart-beating liver graft survival by inhibiting Kupffer cell apoptosis via TLR4-ERK1/2-Fas/FasL-caspase3 pathway regulation
Sheng et al. Transplantation of stromal vascular fraction as an alternative for accelerating tissue expansion
Tanaka et al. The effects of flap ischemia on normal and diabetic progenitor cell function
Luan et al. Implantation of mesenchymal stem cells improves right ventricular impairments caused by experimental pulmonary hypertension
Song et al. Transfection of HGF gene enhances endothelial progenitor cell (EPC) function and improves EPC transplant efficiency for balloon-induced arterial injury in hypercholesterolemic rats
EP4640237A2 (en) Macrophage-based therapy for use in the treatment of acute liver injury
CN114901806B (zh) 细胞群以及其取得方法
Okura et al. Intracoronary artery transplantation of cardiomyoblast-like cells from human adipose tissue-derived multi-lineage progenitor cells improve left ventricular dysfunction and survival in a swine model of chronic myocardial infarction
Swaminathan et al. Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis
Madariaga et al. Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma
US20250152633A1 (en) Cells having improved proliferative capacity and reduced cellular senescence
Tousoulis et al. Infusion of lin−/sca-1+ and endothelial progenitor cells improves proinflammatory and oxidative stress markers in atherosclerotic mice
EP2607478A1 (en) Phenanthroline treated MSC
HK40008604A (zh) 用於改善细胞、组织和器官的活力和功能的试剂、组合物和方法
Guo et al. Myoblast-based cardiac repair: xenomyoblast versus allomyoblast transplantation
Tan et al. The expression of HMGB1 in bone marrow MSCs is upregulated by hypoxia with regulatory effects on the apoptosis and adhesion
Clancy Autologous cells for renal allograft repair
LeBlanc State of the Field: Cellular and Exosomal Therapeutic Approaches in Vascular Regeneration 2
Lewis-McDougall et al. Senescent, dysfunctional human cardiac progenitor cells (CPCs) accumulate in the aged heart and elimination of senescent cells enhances CPC activation and cardiomyocyte proliferation in aged mice
IZUMIDA et al. The Recruitment of Bone Marrow-Derived Cells to Sites of Pancreatic β-cell Injury and the Restoration of Endocrine Function
Marsboom et al. Vascular Repair and Regeneration by Endothelial Progenitor Cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220112

R150 Certificate of patent or registration of utility model

Ref document number: 7009463

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250